LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (45)
2023
-
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome
Clinical Lung Cancer, Vol. 24, Núm. 5, pp. 415-428
-
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
ESMO Open, Vol. 8, Núm. 4
2022
-
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
npj Breast Cancer, Vol. 8, Núm. 1
-
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer
Future oncology (London, England), Vol. 18, Núm. 28, pp. 3133-3141
2021
-
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer
Clinical Cancer Research, Vol. 27, Núm. 4, pp. 992-1003
-
RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non⇓small cell lung cancer
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5258-5271
2019
2018
-
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
Journal of Thoracic Oncology, Vol. 13, Núm. 2, pp. 165-183
-
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study
Journal of Thoracic Oncology, Vol. 13, Núm. 2, pp. 228-236
-
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer
Clinical Lung Cancer, Vol. 19, Núm. 2, pp. 130-138.e2
-
Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Current Medical Research and Opinion, Vol. 34, Núm. 5, pp. 865-871
-
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Lung Cancer, Vol. 124, pp. 53-64
-
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
Clinical Lung Cancer, Vol. 19, Núm. 4, pp. 331-339
-
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non–Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care
Clinical Lung Cancer, Vol. 19, Núm. 6, pp. e823-e830
-
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell Lung Cancer (RELAY): Phase Ib Results
Clinical Lung Cancer, Vol. 19, Núm. 3, pp. 213-220.e4
-
Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis
Thrombosis Research, Vol. 167, pp. 50-56
2017
-
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer
Lung Cancer, Vol. 108, pp. 212-216
-
Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer
Lung Cancer, Vol. 104, pp. 45-51
-
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
Annals of Oncology, Vol. 28, Núm. 12, pp. 2932-2942
-
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
Lung Cancer, Vol. 112, pp. 181-187